Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H11NO3S |
| Molecular Weight | 201.243 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2CC(=O)N2[C@H]1C(O)=O
InChI
InChIKey=RBKMMJSQKNKNEV-RITPCOANSA-N
InChI=1S/C8H11NO3S/c1-8(2)6(7(11)12)9-4(10)3-5(9)13-8/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1
| Molecular Formula | C8H11NO3S |
| Molecular Weight | 201.243 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. | 2003-03 |
|
| Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet. | 2003-03 |
|
| Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases. | 2003-03 |
|
| Sciatic nerve palsy as presenting sign of a perianal abscess. | 2003-02 |
|
| Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. | 2003-02 |
|
| Biotechnological applications of penicillin acylases: state-of-the-art. | 2003-01 |
|
| Enzymatic synthesis of amoxicillin: avoiding limitations of the mechanistic approach for reaction kinetics. | 2002-12-20 |
|
| The penicillins: a review and update. | 2002-12-18 |
|
| Postoperative infection with group A beta-hemolytic Streptococcus after blepharoplasty. | 2002-12 |
|
| Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. | 2002-11 |
|
| Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam. | 2002-11 |
|
| Factors governing intrinsic chemical reactivity differences between clavulanic and penicillanic acids. | 2002-10-09 |
|
| In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. | 2002-10 |
|
| Piperacillin/Tazobactam inducing seizures in a hemodialysed patient. | 2002-10 |
|
| The effect of antibiotic rotation on colonization with antibiotic-resistant bacilli in a neonatal intensive care unit. | 2002-10 |
|
| Quantitative characterization of the nucleophile reactivity in penicillin acylase-catalyzed acyl transfer reactions. | 2002-09-23 |
|
| General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. | 2002-09-01 |
|
| Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. | 2002-09 |
|
| [Piperacillin-tazobactam also at home]. | 2002-09 |
|
| Morganella morganii causing solitary liver abscess complicated by pyopericardium and left pleural effusion in a nondiabetic patient. | 2002-09 |
|
| Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. | 2002-09 |
|
| Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. | 2002-09 |
|
| Successful medical management of emphysematous pyelonephritis. | 2002-08-15 |
|
| New and rapid fully automated method for determination of tazobactam and piperacillin in fatty tissue and serum by column-switching liquid chromatography. | 2002-08-05 |
|
| Synthesis and biological evaluation of 6-bromo-6-substituted penicillanic acid derivatives as beta-lactamase inhibitors. | 2002-08 |
|
| Selection of oxacillin resistance in oxacillin-sensitive Staphylococcus aureus through exposure to ciprofloxacin but not piperacillin/tazobactam. | 2002-08 |
|
| Lemierre's disease caused by co-infection of Arcanobacterium haemolyticum and Fusobacterium necrophorum: a case report. | 2002-08 |
|
| Jet-black eschar. | 2002-08 |
|
| Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder. | 2002-07-31 |
|
| Role of alphaArg145 and betaArg263 in the active site of penicillin acylase of Escherichia coli. | 2002-07-01 |
|
| Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry. | 2002-07-01 |
|
| Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. | 2002-07 |
|
| Infecting one animal with two different strains of the same bacteria may cause misleading results. | 2002-07 |
|
| Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. | 2002-07 |
|
| Penicillin acylase-catalyzed ampicillin synthesis using a pH gradient: a new approach to optimization. | 2002-06-05 |
|
| Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. | 2002-06-01 |
|
| [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam]. | 2002-06 |
|
| Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. | 2002-06 |
|
| Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors. | 2002-06 |
|
| Equilibrium modeling of extractive enzymatic hydrolysis of penicillin G with concomitant 6-aminopenicillanic acid crystallization. | 2002-05-20 |
|
| Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. | 2002-05 |
|
| Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. | 2002-05 |
|
| Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. | 2002-05 |
|
| [A multicenter clinical trial of piperacillin/tazobactam in burn infection]. | 2002-04 |
|
| Synthesis of new C-6 alkyliden penicillin derivatives as beta-lactamase inhibitors. | 2002-04 |
|
| [Piperacillin-tazobactam in the treatment of severe nosocomial infections]. | 2002-03 |
|
| [Study on water of crystallization in tazobactam]. | 2002-02 |
|
| [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus]. | 2002-02 |
|
| Mycotic aneurysm of the descending thoracic aorta caused by Pseudomonas aeruginosa in a solid organ transplant recipient: case report and review. | 2002 |
|
| [Determination of degraded products of penicillin by high performance liquid chromatography]. | 2001-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:59:38 GMT 2025
by
admin
on
Mon Mar 31 21:59:38 GMT 2025
|
| Record UNII |
PIS09H0QIX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6891
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | |||
|
DTXSID90236038
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | |||
|
PIS09H0QIX
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | |||
|
87-53-6
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | |||
|
201-750-3
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | |||
|
m8470
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
37806
Created by
admin on Mon Mar 31 21:59:38 GMT 2025 , Edited by admin on Mon Mar 31 21:59:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
